Navigation Links
Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010
Date:9/25/2010

ion Imaging

MPI studies, commonly called cardiac stress tests, identify areas of poor blood flow in the heart to determine the extent of coronary artery disease (CAD)(2), a condition that affects about 17.5 million(3) Americans each year. Though many patients exercise on a treadmill to generate the increase in coronary blood flow necessary to perform an MPI study, almost half who undergo cardiac stress tests are unable to exercise adequately because of medical conditions(4). For these patients, a pharmacologic stress agent that temporarily increases blood flow through the coronary arteries is used to mimic the increase in coronary blood flow achieved by exercise.

About Lexiscan

Lexiscan is an A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide MPI in patients unable to undergo adequate exercise stress. Lexiscan was designed to produce coronary vasodilation and increase coronary blood flow by activation of the A2A adenosine receptor. Lexiscan is administered as a standard dose intravenous injection (approximately 10 seconds).

Important Safety Information

Do not administer Lexiscan to patients with second- or third-degree AV block or sinus node dysfunction unless these patients have a functioning artificial pacemaker.

Fatal cardiac arrest, life-threatening ventricular arrhythmias, and myocardial infarction may result from the ischemia induced by pharmacologic stress agents. Cardiac resuscitation equipment and trained staff should be available before administering Lexiscan.

Adenosine receptor agonists, including Lexiscan, can depress the SA and AV nodes and may cause first-, second-, or third-degree AV block, or sinus bradycardia requiring intervention. In postmarketing experience, heart block (including third degree), and asystole within minutes of Lexiscan administration have occurred.

Adenosine receptor agonists,
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
8. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
9. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 /CNW/ - More than fifty years ago, Thalidomide was ... in expectant mothers. Tragically, Thalidomide caused serious and permanent physical ... Support has been provided to survivors over the years ... Canada in 1991 and settlements from drug companies. ... obligation to provide support, we have a clear moral obligation ...
(Date:5/22/2015)... , May 22, 2015  BioLife Solutions, Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and cryopreservation ... for cells and tissues ("BioLife" or the "Company"), announced that ... MicroCap Conference. The Company is scheduled to ... May 27, 2015 at the Grand Hyatt Hotel in ...
(Date:5/22/2015)... May 22, 2015 Electrophysiologist Kevin Makati, ... traveled to Boston, MA ... 2015 Heart Rhythm Society conference. These scientific sessions ... on the ideas, people and technology that propel ... a hybrid, minimally invasive cardiac operation that combines ...
Breaking Medicine Technology:Statement from Minister Ambrose on Thalidomide 2Statement from Minister Ambrose on Thalidomide 3BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3
... 2011  Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE)("Ampio" or the "Company"), ... previously approved drugs and new molecular entities ("NMEs"), announced ... accredited investors to sell an aggregate approximately 2,220,255 of ... share (the "Shares"), at a price per share of ...
... Radiologic (vRad), a technology-enabled national radiology practice, ... Montgomery Radiology Associates (MRA) have joined its ... Inc. (DII). These former MRA radiologists will ... (PMMC) and join the more than 60 ...
Cached Medicine Technology:Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million 2Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million 3vRad Radiology Alliance Continues to Transform Radiology With Most Recent Practice Partnership 2
(Date:5/25/2015)... 2015 The National Association ... Heather Stanley-Christian as a 2015-2016 inductee into ... is recognized with this prestigious distinction for leadership ... organization exclusively for professional women, boasting more than ... , "I'm pleased to welcome Heather into this ...
(Date:5/25/2015)... 2015 24Hr HomeCare is proud to ... Co-Founder & COO, and Ryan Iwamoto, Co-Founder & CMO, ... The Year® 2015 Awards in Greater Los Angeles. The ... excellence in innovation, financial performance, and a personal commitment ... core of the ongoing success of our organization,” said ...
(Date:5/25/2015)... ProDrop Light Show allows users to now have ability ... click of a mouse. Users have full control over angle of ... Pro X. , ProDrop Light Show gives users 30 fully customizable ... more leaving infinite possibilities all within Final Cut Pro X. , ... users can apply their very own media files or text all ...
(Date:5/25/2015)... May 25, 2015 Decora Preset 60 ... is now available on ‘The Hardware City.’ The product helps ... to set a time and the related electronic device is ... a representative of the company said, “We are glad that ... Now customers can buy Countdown Timer Switch in just a ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 Women’s ... to take pressure measurements in patients’ bladder and urethra. ... usually orders it if they have reported symptoms of ... , Women’s Excellence in Bladder Control is a ... urinary leakage or problems with overall control of their ...
Breaking Medicine News(10 mins):Health News:NAPW Inducts Dr. Heather Stanley-Christian, Systems Chair/Maternal Fetal Medicine at Stroger Hospital, into Its VIP Professional Woman of the Year Circle 2Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2Health News:Leviton's Decora 60 Minute Countdown Timer Available On ‘The Hardware City’ 2
... dental expert notes importance of regular oral care to protect ... Results from a 2008 Gallup-Healthways poll(1) show that 42 percent ... 12 months, even though the American Dental Association recommends having ... percent of all Americans responded that they did not see ...
... and Sustained Pain Relief for up to 48 Hours -- ... - MOUNTAIN VIEW, Calif., May 26 MAP Pharmaceuticals, Inc. ... portion of its first Phase 3 clinical trial evaluating its ... endpoints. Additional endpoints showed that LEVADEX provided rapid and ...
... Inc. (Pink Sheets: FTER), owner and operator of the "A ... that an advertisement for "A Better Tomorrow" will appear on ... May and June.The ad, which can be viewed at ... offers a safe, caring, relaxing place to face addiction head ...
... Veracord™, ( www.veracord.com ), a privately held ... Parasoft® Corporation, a leading provider of automated ... the Parasoft award-winning product offering beyond product ... compliance. Together, Veracord and Parasoft offer clients ...
... is presented at The Association for Research in Vision and ... "Accuracy of Transpalpebral Tonometer Diaton Compared to Goldmann Applanation ... Dr. Mark Latina, the inventor of Selective Laser Trabeculoplasty (SLT). ... ...
... of industries like WLAN networks, telecommunication, wireless security, ... experiments, traffic control & Audio/Video, Pro-cell antenna-related goods ... in the Taipei World Trade Exhibition -- COMPUTEX ... the world, next only to CeBIT in Hannover, ...
Cached Medicine News:Health News:Hispanics Placing Their Oral Health at Risk by Cutting Back on Routine Dental Care 2Health News:Hispanics Placing Their Oral Health at Risk by Cutting Back on Routine Dental Care 3Health News:MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints 2Health News:MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints 3Health News:MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints 4Health News:MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints 5Health News:MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints 6Health News:MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints 7Health News:Veracord and Parasoft Partner to Improve Compliance and Reduce Cost 2Health News:Veracord and Parasoft Partner to Improve Compliance and Reduce Cost 3Health News:Thumbs Up at ARVO for Diaton Tonometer - New Through Eyelid Glaucoma Test Clinical Study Presented, Results as Accurate as Gold Standard 2Health News:Thumbs Up at ARVO for Diaton Tonometer - New Through Eyelid Glaucoma Test Clinical Study Presented, Results as Accurate as Gold Standard 3Health News:Pro-cell Announces a Knock at the Door of Emerging Markets 2Health News:Pro-cell Announces a Knock at the Door of Emerging Markets 3Health News:Pro-cell Announces a Knock at the Door of Emerging Markets 4
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: